POP Biotechnologies Inc.
Buffalo, NY · Biotech · Private
SNAP-AD, a multivalent nanoparticle vaccine targeting multiple epitopes of amyloid-beta and tau proteins for Alzheimer's disease treatment
- Grants
- $9.6M
- 19 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 1
- 1 granted · 0 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Scalable Formulation and Production of Photosensitive Nanoparticles for Cancer Therapy | $224,205 | |
| Federal grant | Department of Health and Human Services · Phase I · Scalable Formulation and Production of Photosensitive Nanoparticles for Cancer Therapy | $55,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · An adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment | $223,797 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · An adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment | $223,797 | |
| Federal grant | Department of Health and Human Services · Phase I · Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin | $399,917 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing a Thermostable SARS-CoV-2 RBD-particle Vaccine | $299,991 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing a Thermostable SARS-CoV-2 RBD-particle Vaccine | $299,991 | |
| Federal grant | Department of Health and Human Services · Phase II · Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin | $1,001,404 | |
| Federal grant | Department of Health and Human Services · Phase I · Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes | $248,855 | |
| Federal grant | Department of Health and Human Services · Phase I · Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes | $248,855 | |
| Federal grant | Department of Health and Human Services · Phase II · Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin | $998,596 | |
| Federal grant | Department of Health and Human Services · Phase II · Advanced testing of a hexavalent adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment | $950,225 | |
| Federal grant | Department of Health and Human Services · Phase I · Liposome-displayed peptide vaccine against disseminated candidiasis by clinically-relevant Candida species | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes | $247,714 | |
| Federal grant | Department of Health and Human Services · Phase II · Advanced testing of a hexavalent adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment | $949,201 | |
| Federal grant | Department of Health and Human Services · Phase I · Liposome-displayed peptide vaccine against disseminated candidiasis by clinically-relevant Candida species | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes | $833,334 | |
| Federal grant | Department of Health and Human Services · Phase II · Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes | $822,289 | |
| Federal grant | Department of Health and Human Services · Phase II · Advanced testing of a hexavalent adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment | $948,983 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3336 | ABBRATECH INC. | — | — |
| 3337 | PURE BIOSCIENCE, INC. | — | $29M |
| 3338 | Timberlyne Therapeutics | — | — |
| 3339 | POP Biotechnologies Inc. | — | — |
| 3340 | SiMPore, Inc. | — | $1.0M |
| 3341 | DATIRIUM LLC | — | — |
| 3342 | Stealth Biosciences, Inc | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.